URL copied
Covaxin generated excellent safety data, says Bharat Biotech
Amid the criticism of the Drug Controller General of India (DCGI) for granting approval for the emergency use of Covid-19 vaccine Covaxin, its manufacturer Bharat Biotech claimed on Sunday that its vaccine generated excellent safety data with robust immune responses to multiple viral proteins that persist.
Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses, the Hyderabad-based company said in a statement. The evaluation of Covaxin has resulted in several unique product characteristics including long term persistence of immune responses to multiple viral proteins, as opposed to only the spike protein, and has demonstrated broad-spectrum neutralising capability with heterologous SARS-CoV2 strains, thus potentially reducing or eliminating escape mutants, it said.
India to play vital role in equitable distribution of COVID-19 vaccines around the world: Pharma industry
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
India reports 22,272 new COVID-19 cases in last 24 hours
indiagazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiagazette.com Daily Mail and Mail on Sunday newspapers.
India logs 22,272 new coronavirus cases, 251 deaths ANI | Updated: Dec 26, 2020 11:52 IST
New Delhi [India], December 26 (ANI): With 22,272 new COVID-19 cases recorded in the last 24 hours, India s infections tally has reached 1,01,69,118, informed the Union Ministry of Health and Family Welfare on Saturday.
The country witnessed 251 new COVID-19 deaths during the same period, taking the cumulative toll to 1,47,343. At present, there are 2,81,667 active cases, while the overall recoveries have reached 97,40,108 as 22,274 people were discharged in the last 24 hours.
As many as 16,71,59,289 samples were tested up to December 25, including 8,53,527 samples tested on Friday, according to the Indian Council of Medical Research (ICMR).
Meanwhile, Bharat Biotech Chairman and Managing Director Dr Krishna Ella and Joint Managing Director Suchitra Ella had called on Vice President M Venkaiah Naidu in Hyderabad to discuss the status of the indigenou
Updated Dec 24, 2020 | 11:03 IST
On the distribution of vaccines in India, he said India is well prepared for that and Indian immunisation system is very robust, Ella said. People who have been infected with COVID-19 should also take vaccine, says Bharat Biotech Chairman | Photo Credit: iStock Images
New Delhi: People who are infected should also take a vaccine, and India is well prepared regarding the logistics for the vaccine distribution, Bharat Biotech, Chairman & MD Krishna Ella said on Wednesday.
He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post-vaccination era organised by industry body CII.